ACAD vs HAE
ACADIA Pharmaceuticals Inc. vs Haemonetics — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
67
Buy
VS
| Metric | ACAD | HAE |
|---|
| AI Score |
67
|
49
|
| Price |
$29.66
|
$108.42
|
| P/E Ratio |
13.11×
|
52.82×
|
| ROE |
31.9%
|
12.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
57.4%
|
| Debt / Equity |
0.06×
|
1.40×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
59.6
|
90.2
|
| Beta |
0.845
|
0.518
|
| Expected Upside |
—
|
+30.2%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus HAE.
ACAD leads by 18 points.
ACAD scores 67/100 (Buy) versus HAE at 49/100 (Watch).
ACAD Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
HAE Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 1.54) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Debt-to-equity of 1.54 adds balance-sheet risk to the value case — Value
- EPS declining -37.4% YoY despite any revenue growth — Growth